Abstract
Propargylamine is a chemical moiety whose properties have made it a widely distributed group within the fields of medicinal chemistry and chemical biology. Its particular reactivity has traditionally popularized the preparation of propargylamine derivatives using a large variety of synthetic strategies, which have facilitated the access to these compounds for the study of their biomedical potential. This review comprehensively covers and analyzes the applications that propargylamine-based derivatives have achieved in the drug discovery field, both from a medicinal chemistry perspective and from a chemical biology-oriented approach. The principal therapeutic fields where propargylamine-based compounds have made an impact are identified, and a discussion of their influence and growing potential is included.
Graphical abstract
Tweetable abstract
Propargylamine derivatives are commonly present in various areas of #drugdiscovery. In this new @fsgfmc review article, scientists @aitorcarneiro and @mariacmatos from @UPorto and @UniversidadeUSC discuss the reasons underlying recent uses and applications of these compounds.
Papers of special note have been highlighted as: • of interest; •• of considerable interest
References
- 1. . Ueber einige ungesättigte Amine der aliphatischen Reihe. Ber. Dtsch. Chem. Ges. 24(2), 3035–3048 (1891).
- 2. . Synthesis and reactivity of propargylamines in organic chemistry. Chem. Rev. 117(24), 14091–14200 (2017). •• Extensive and complete review of the relevance of propargylamine and its derivatives in organic synthesis.
- 3. . A depropargylation-triggered fluorescence “turn-on” probe for the detection of Pd2+ based on a bispropargylamine–rhodamine conjugate. Analyst 138(5), 1564–1569 (2013).
- 4. Structure-activity relationship of propargylamine-based HDAC inhibitors. ChemMedChem 12(24), 2044–2053 (2017).
- 5. . Propargylamine as functional moiety in the design of multifunctional drugs for neurodegenerative disorders: MAO inhibition and beyond. Future Med. Chem. 7(5), 609–629 (2015).
- 6. . Propargylamine-selective dual fluorescence turn-on method for post-synthetic labeling of DNA. Chem. Commun. 56(21), 3199–3202 (2020).
- 7. Novel arylalkenylpropargylamines as neuroprotective, potent, and selective monoamine oxidase B inhibitors for the treatment of Parkinson's disease. J. Med. Chem. 58(3), 1400–1419 (2015).
- 8. . Metabolism and pharmacokinetics, in the rat, of (R)-N-(2-heptyl)methyl-propargylamine (R-2HMP), a new potent monoamine oxidase inhibitor and antiapoptotic agent. Drug Metab. Dispos. 28(2), 147–154 (2000).
- 9. . New insights in the metabolism of oxybutynin: evidence of N-oxidation of propargylamine moiety and rearrangement to enaminoketone. Xenobiotica 48(5), 478–487 (2018). • Provides evidence about potential metabolic transformations that the propargylamine moiety may undergo.
- 10. . Acetylene group, friend or foe in medicinal chemistry. J. Med. Chem. 63(11), 5625–5663 (2020). • Highlights the advantages and drawbacks of the acetylene group in medicinal chemistry.
- 11. . Inhibitors of MAO-B and COMT: their effects on brain dopamine levels and uses in Parkinson's disease. J. Neural Transm. 126(4), 433–448 (2019).
- 12. . MAO inhibitors and their wider applications: a patent review. Expert Opin. Ther. Pat. 28(3), 211–226 (2018).
- 13. . Privileged scaffolds as MAO inhibitors: retrospect and prospects. Eur. J. Med. Chem. 145(10), 445–497 (2018).
- 14. . Characterization of the covalently bound anionic flavin radical in monoamine oxidase A by electron paramagnetic resonance. J. Am. Chem. Soc. 129(51), 16091–16097 (2007).
- 15. . Questions in the chemical enzymology of MAO. Chemistry 3(3), 959–978 (2021).
- 16. . Structure-activity relations in the pargyline series. Ann. NY Acad. Sci. 107(3), 891–898 (1963).
- 17. . N-Methyl-N-2-propynyl-1-indanamine. A potent monoamine oxidase inhibitor. J. Med. Chem. 9(6), 830–832 (1966).
- 18. . Phenylisopropylmethylpropinylamine (E-250), a new spectrum psychic energizer. Arch. Int. Pharmacodyn. Ther. 155(1), 154–164 (1965).
- 19. . Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem. Pharmacol. 17(7), 1285–1297 (1968).
- 20. . Some puzzling pharmacological effects of monoamine oxidase inhibitors. Adv. Biochem. Psychopharmacol. 5, 393–408 (1972).
- 21. . Medicinal chemistry of present and future MAO-B inhibitors. In: Inhibitors of Monoamine Oxidase B. Szelenyi I (Eds). Birkhäuser, Basel, Switzerland 75– 108 (1993).
- 22. . MAO-B inhibitors: multiple roles in the therapy of neurodegenerative disorders? Parkinsonism Relat. Disord. 6(1), 25–47 (2000).
- 23. . Computational insight into the mechanism of the irreversible inhibition of monoamine oxidase enzymes by the antiparkinsonian propargylamine inhibitors rasagiline and selegiline. ACS Chem. Neurosci. 10(8), 3532–3542 (2019).
- 24. . Kinetics, mechanism, and inhibition of monoamine oxidase. J. Neural Transm. (Vienna) 125(11), 1659–1683 (2018).
- 25. Parameters for irreversible inactivation of monoamine oxidase. Molecules 25(24), 5908 (2020).
- 26. . Evidence for a cyanine link between propargylamine drugs and monoamine oxidase clarifies the inactivation mechanism. Front. Chem. 6, 169 (2018). •• Proposes a mechanism of action for propargylamine-based monoamine oxidase inhibitors to act as suicide inhibitors, irreversibly binding to flavin adenine dinucleotide.
- 27. . Structure of the human mitochondrial monoamine oxidase B: new chemical implications for neuroprotectant drug design. Neurology 67(2 Suppl. 7), S5–S7 (2006).
- 28. Binding of rasagiline-related inhibitors to human monoamine oxidases: a kinetic and crystallographic analysis. J. Med. Chem. 48(26), 8148–8154 (2005).
- 29. Stereoselective activity of 1-propargyl-4-styrylpiperidine-like analogues that can discriminate between monoamine oxidase isoforms A and B. J. Med. Chem. 63(3), 1361–1387 (2020). • Focuses on the development of a pair of cis/trans isomers that can discriminate between both monoamine oxidase-A and B isoforms.
- 30. . Coumarin-rasagiline hybrids as potent and selective hMAO-B inhibitors, antioxidants, and neuroprotective agents. ChemMedChem 15(6), 532–538 (2020).
- 31. Comparative analysis of the neurochemical profile and MAO inhibition properties of N-(furan-2-ylmethyl)-N-methylprop-2-yn-1-amine. ACS Chem. Neurosci. 8(5), 1026–1035 (2017).
- 32. Novel propargylamine-based inhibitors of cholinesterases and monoamine oxidases: synthesis, biological evaluation and docking study. Bioorg. Chem. 116, 105301 (2021).
- 33. Classics in neuroimaging: development of PET tracers for imaging monoamine oxidases. ACS Chem. Neurosci. 10(4), 1867–1871 (2019).
- 34. . Multi-target-directed ligands to combat neurodegenerative diseases. J. Med. Chem. 51(3), 347–372 (2008).
- 35. . 7-Amidocoumarins as multitarget agents against neurodegenerative diseases: substitution pattern modulation. ChemMedChem 16(1), 179–186 (2020).
- 36. Synthesis, pharmacological study and docking calculations of new benzo[f]coumarin derivatives as dual inhibitors of enzymatic systems involved in neurodegenerative diseases. Future Med. Chem. 6(4), 371–383 (2014).
- 37. Study of coumarin-resveratrol hybrids as potent antioxidant compounds. Molecules 20(2), 3290–3308 (2015).
- 38. Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease. J. Med. Chem. 45(24), 5260–5279 (2002). •• Introduces a strategy for dual monoamine oxidase and cholinesterase inhibition.
- 39. . Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment. Curr. Drug Targets 13(4), 483–494 (2012).
- 40. Avraham Pharmaceuticals Ltd Avraham Pharmaceuticals Ltd. Safety and efficacy study of ladostigil in mild to moderate probable Alzheimer's disease.. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01354691 (Accessed 22 February 2022).
- 41. Synthesis, biological evaluation, and molecular modeling of donepezil and N-[(5-(benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease. J. Med. Chem. 54(24), 8251–8270 (2011).
- 42. Donepezil + propargylamine + 8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer's disease. Eur. J. Med. Chem. 80, 543–561 (2014).
- 43. Discovery of novel propargylamine-modified 4-aminoalkyl imidazole substituted pyrimidinylthiourea derivatives as multifunctional agents for the treatment of Alzheimer's disease. Eur. J. Med. Chem. 143, 33–47 (2018).
- 44. Rational design of novel selective dual-target inhibitors of acetylcholinesterase and monoamine oxidase B as potential anti-Alzheimer's disease agents. ACS Chem. Neurosci. 10(1), 482–496 (2019).
- 45. Design, synthesis and evaluation of novel dual monoamine-cholinesterase inhibitors as potential treatment for Alzheimer's disease. Neuropharmacology 109, 376–385 (2016).
- 46. N-Propargylpiperidines with naphthalene-2-carboxamide or naphthalene-2-sulfonamide moieties: potential multifunctional anti-Alzheimer's agents. Bioorg. Med. Chem. 25(2), 633–645 (2017).
- 47. Novel (hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson's disease. Mol. Neurodegener. 11(1), 6 (2016).
- 48. ASS234, as a new multi-target directed propargylamine for Alzheimer's disease therapy. Front. Neurosci. 10, 294 (2016).
- 49. . Upregulation of antioxidant enzymes by ASS234, a multitarget directed propargylamine for Alzheimer's disease therapy. CNS Neurosci. Ther. 22(9), 799–802 (2016).
- 50. N-Benzylpiperidine derivatives as A7 nicotinic receptor antagonists. ACS Chem. Neurosci. 7(8), 1157–1165 (2016).
- 51. . Design, synthesis and evaluation of pentacycloundecane and hexacycloundecane propargylamine derivatives as multifunctional neuroprotective agents. Eur. J. Med. Chem. 163, 83–94 (2019).
- 52. . The importance of propargylamine moiety in the anti- Parkinson drug rasagiline and its derivatives for MAPK-dependent amyloid precursor protein processing. FASEB J. 17(15), 2325–2327 (2003).
- 53. , M30, a novel multifunctional neuroprotective drug with potent iron chelating and brain selective monoamine oxidase-Ab inhibitory activity for Parkinson's disease. In: Parkinson's Disease and Related Disorders. Youdim MBHRiederer PReichmann HGerlach M (Eds). Springer, Vienna, Austria 447–456 (2006).
- 54. . Multi-target neuroprotective and neurorestorative anti-Parkinson and anti-Alzheimer drugs ladostigil and M30 derived from rasagiline. Exp. Neurobiol. 22(1), 1–10 (2013).
- 55. Targeting Alzheimer's disease with multimodal polypeptide-based nanoconjugates. Sci. Adv. 7(13), eabf9180 (2021).
- 56. . Synthesis of propargylamine mycophenolate analogues and their selective cytotoxic activity towards neuroblastoma SH-SY5Y cell line. Bioorg. Med. Chem. Lett. 45, 128135 (2021).
- 57. . Rasagiline and selegiline, inhibitors of type B monoamine oxidase, induce type A monoamine oxidase in human SH-SY5Y cells. J. Neural Transm. 120(3), 435–444 (2012). • Identifies a certain selectivity toward neuroblastoma cell lines over normal cells observed in compounds bearing the propargylamine moiety, such as rasagiline and selegiline.
- 58. Synthesis of propargylamines via the A3 multicomponent reaction and their biological evaluation as potential anticancer agents. Org. Biomol. Chem. 18(13), 2475–2486 (2020).
- 59. . Synthesis of antitumor-active betulinic acid-derived hydroxypropargylamines by copper-catalyzed Mannich reactions. Arch. Pharm. Pharm. Med. Chem. 346(3), 232–246 (2013).
- 60. Structure-activity relationship of propargylamine-based HDAC inhibitors. ChemMedChem 12(24), 2044–2053 (2017).
- 61. Nonpeptidic propargylamines as inhibitors of lysine specific demethylase 1 (LSD1) with cellular activity. J. Med. Chem. 56(18), 7334–7342 (2013).
- 62. Salinomycin derivatives kill breast cancer stem cells by lysosomal iron targeting. Chem. Eur. J. 26(33), 7416–7424 (2020).
- 63. . Polymerase synthesis of DNA labelled with benzylidene cyanoacetamide-based fluorescent molecular rotors: fluorescent light-up probes for DNA-binding proteins. Chem. Commun. 51(23), 4880–4882 (2015).
- 64. . Anti-trypanosomal activity of doubly modified salinomycin derivatives. Eur. J. Med. Chem. 173, 90–98 (2019).
- 65. Synthesis and evaluation of 5-substituted 2′-deoxyuridine monophosphate analogues as inhibitors of flavin-dependent thymidylate synthase in Mycobacterium tuberculosis. J. Med. Chem. 54(13), 4847–4862 (2011).
- 66. Structure-based design of lipophilic quinazoline inhibitors of thymidylate synthase. J. Med. Chem. 39(4), 904–917 (1996).
- 67. Ligand efficiency driven design of new inhibitors of Mycobacterium tuberculosis transcriptional repressor EthR using fragment growing, merging, and linking approaches. J. Med. Chem. 57(11), 4876–4888 (2014).
- 68. Identification of the 4-position of 3-alkynyl and 3-heteroaromatic substituted pyridine methanamines as a key modification site eliciting increased potency and enhanced selectivity for cytochrome P-450 2A6 inhibition. J. Med. Chem. 61(16), 7065–7086 (2018).
- 69. . Copper-catalyzed azide–alkyne cycloaddition (CuAAC) and beyond: new reactivity of copper(I) acetylides. Chem. Soc. Rev. 39(4), 1302 (2010). •• Exemplifies an important bio-orthogonal click chemistry reaction that may be accessible to relevant compounds by introducing a propargylamine residue.
- 70. . The highly sensitive and facile colorimetric detection of the glycidyl azide polymer based on propargylamine functionalized gold nanoparticles using click chemistry. Chem. Commun. 51(60), 12092–12094 (2015).
- 71. Shortcut to high-affinity Ga-68 and Cu-64 radiopharmaceuticals: one-pot click chemistry trimerisation on the TRAP platform. Dalton Trans. 44(24), 11137–11146 (2015).
- 72. Highly selective fluorescent probe for Au3+ based on cyclization of propargylamide. Chem. Commun. 46, 7218 (2009).
- 73. Highly selective ratiometric fluorescent probe for Au3+ and its application to bioimaging. Biosens. Bioelectron. 49, 438–441 (2013).
- 74. Site-specific protein propargylation using tissue transglutaminase. Org. Biomol. Chem. 10(27), 5258 (2012).
- 75. . Gold compounds for catalysis and metal-mediated transformations in biological systems. Curr. Opin. Chem. Biol. 55, 103–110 (2020).
- 76. . The highly sensitive and facile colorimetric detection of the glycidyl azide polymer based on propargylamine functionalized gold nanoparticles using click chemistry. Chem. Commun. 51(60), 12092–12094 (2015).
- 77. . A clickable inhibitor reveals context-dependent autoactivation of p90 RSK. Nat. Chem. Biol. 3, 156–160 (2007).
- 78. . Synthesis of an O-alkynyl-chitosan and its chemoselective conjugation with a PEG-like amino-azide through click chemistry. Carbohydr. Polym. 87(1), 240–249 (2012).
- 79. . First “click” synthesis of the ribbed-functionalized metal clathrochelates: cycloaddition of benzyl azide to propargylamine iron(II) macrobicycle and the unexpected transformations of the resulting cage complex. Eur. J. Inorg. Chem. 2012(28), 4507–4514 (2012).